Flexicath Announces FDA Clearance of the Pressure Injectable M/29 Midterm® Catheter Series
PITTSBURGH, Aug. 23, 2012 /PRNewswire/ — Flexicath, Inc., the Pittsburgh-based medical device company that develops, manufactures and markets sterile catheter insertion systems that are targeted to address catheter-related blood stream infection control issues and the need for a simple-to-place intermediate dwell catheter, announced today that the company has received FDA clearance for the Pressure Injectable M/29 Midterm® Catheter Series, the latest addition to the M/29 family of midline catheters.
The M/29 Midterm® is the world’s first IV catheter solution to provide a “built in” 360-degree Maximum Barrier® against airborne and touch-borne contamination during the insertion process and offers a simple to place intermediate dwell alternative for patients needing IV therapy for less than 30 days. The M/29 product suite now includes pressure injection rating up to 5 ml/sec, 3 FR catheters in 10 CM and 20CM lengths, and OTN Safety Introducers in 5CM and 7CM lengths. These new product capabilities extend the application of the M/29 in the clinical setting and include ultrasound assisted placement and contrast agent administration – providing additional tools for the vascular access specialist, improving patient satisfaction, and enabling better care.
About Flexicath, Inc.
Flexicath is a medical device company that develops, manufactures, and markets sterile catheter insertion systems that are targeted to address catheter related ‘blood stream infection control issues’ and the need for a simple-to-place intermediate dwell catheter. Flexicath, Inc. has North American headquarters in Pittsburgh, Pennsylvania, and is a wholly owned subsidiary of Flexicath, LTD, headquartered in Tel Aviv, Israel. For additional information, visit www.flexicath.com
About the Pittsburgh Life Sciences Greenhouse (PLSG)
PLSG invests in and supports the growth of biosciences companies in western Pennsylvania. PLSG has a track record of excellence when it comes to attracting and growing life sciences companies in the region. Since its inception in 2002, the PLSG has invested $17.9 million in 71 companies which has leveraged $733 million in additional capital to the region. The PLSG portfolio of companies represents an aggregate market valuation which the PLSG believes it conservatively estimates as over $1 billion. The PLSG has assisted 375 life sciences companies and has helped create or retain nearly 6,000 jobs in western Pennsylvania. In addition, 34 companies or venture capital firms have been provided with office or laboratory space and 13 have been relocated to Pittsburgh from outside of the region. www.plsg.com
SOURCE Pittsburgh Life Sciences Greenhouse